Pharmaceutical Executive Warren Whitehead Joins Amorfix as Chief Financial
TORONTO, Jan. 31, 2013 /CNW/ - Amorfix Life Sciences Ltd. announced today that
Mr. Warren Whitehead has joined the Company as Chief Financial Officer
effective February 1, 2013. Janet Clennett will continue on as part of the
management team and will assume the position of Director of Finance.
Mr. Whitehead has been in the pharmaceutical industry for more than 25 years
and has previously held top management positions in a number of leading
private and publicly owned pharmaceutical companies. Prior to joining
Amorfix, Mr. Whitehead was CFO at Arius Research Inc., where he provided
financial guidance and leadership during the acquisition of ARIUS by Roche in
2008 and prior to that he was CFO at Labopharm, Inc. where he completed a
series of public equity financings and a NASDAQ IPO. He is currently a member
of the Board of Directors of PlantForm Corporation and of Lorus Therapeutics.
"We are pleased to have such an experienced financial executive join the
senior management at Amorfix", said Dr. Robert Gundel, Amorfix President and
Chief Executive Officer. "Mr. Whitehead's financial expertise and his vast
experience in both the biotechnology industry and the financial sector will
provide the necessary leadership to advance our products through to
commercialization, while maximizing returns to our shareholders".
Dr. Neil Cashman, Amorfix founder and Chairman of the Board said, "On behalf
of the Board of Directors, I would like to thank Janet Clennett for all of her
hard work and dedication to Amorfix over the past few years and we are pleased
that Ms. Clennett will remain as a valuable member of the Amorfix management
team in her new role. We welcome Mr. Whitehead to the Company and look
forward to working with him as part of the management team."
Amorfix Life Sciences Ltd. (TSX:AMF) is an early-stage product development
company developing therapeutic antibodies and diagnostics targeting misfolded
protein diseases. Amorfix utilizes its computational discovery platform,
ProMIS™, to predict novel Disease Specific Epitopes (DSEs) on the molecular
surface of misfolded proteins. Using this technology, Amorfix is developing
novel antibody therapeutics and companion diagnostics for cancer and
amyotrophic lateral sclerosis (ALS). In addition, Amorfix has developed two
proprietary technologies to specifically identify very low levels of misfolded
proteins in a biological sample: Epitope Protection™ and AMFIA™, an
ultra-sensitive dual-bead immunoassay. Use of these technologies has
generated a cerebrospinal fluid (CSF) screening test for both Alzheimer's
disease (AD) and mild cognitive impairment (MCI), and an ultrasensitive method
for detecting the hallmark of AD, aggregated beta-Amyloid, in brain tissue,
CSF and blood from animal models of AD. For more information about Amorfix,
The TSX has not reviewed and does not accept responsibility for the adequacy
or accuracy of this release. This information release may contain certain
forward-looking information. Such information involves known and unknown
risks, uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from those implied by
statements herein, and therefore these statements should not be read as
guarantees of future performance or results. All forward-looking statements
are based on the Company's current beliefs as well as assumptions made by and
information currently available to it as well as other factors. Readers are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by the Company
in its public securities filings, actual events may differ materially from
current expectations. The Company disclaims any intention or obligation to
update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise, unless required by law.
ProMIS™, Epitope Protection™ and AMFIA™ are trademarks of Amorfix Life
Dr. Robert Gundel President and Chief Executive Officer Amorfix Life Sciences
Ltd. Tel: (416) 847-6957 Fax: (416) 847-6899 email@example.com
SOURCE: Amorfix Life Sciences Ltd.
To view this news release in HTML formatting, please use the following URL:
CO: Amorfix Life Sciences Ltd.
NI: MTC 2575 WNEWS
-0- Jan/31/2013 12:00 GMT
Press spacebar to pause and continue. Press esc to stop.